NCT01740362View on ClinicalTrials.gov

Pharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

March 31, 2004

Study Completion Date

March 31, 2004

Conditions

Renal Impairment

Interventions

DRUG

CP-690,550

10 mg (2 x 5 mg tablets), single dose

DRUG

CP-690,550

10 mg (2 x 5 mg tablets), single dose

DRUG

CP-690,550

10 mg (2 x 5 mg tablets), single dose

DRUG

CP-690,550

10 mg (2 x 5 mg tablets), single dose

Trial Locations (4)

32806

Pfizer Investigational Site, Orlando

55404

Pfizer Investigational Site, Minneapolis

70118

Pfizer Investigational Site, New Orleans

70119

Pfizer Investigational Site, New Orleans

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY

NCT01740362 - Pharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function | Biotech Hunter | Biotech Hunter